Bcal Diagnostics Ltd (BDX) - Total Liabilities
Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) has total liabilities worth AU$4.68 Million AUD (≈ $3.31 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Bcal Diagnostics Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Bcal Diagnostics Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Bcal Diagnostics Ltd's total liabilities have evolved over time, based on quarterly financial data. See Bcal Diagnostics Ltd (BDX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Bcal Diagnostics Ltd Competitors by Total Liabilities
The table below lists competitors of Bcal Diagnostics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dignitana AB
ST:DIGN
|
Sweden | Skr24.80 Million |
|
Southern Energy Corp
V:SOU
|
Canada | CA$35.51 Million |
|
Asia Poly Holdings Bhd
KLSE:0105
|
Malaysia | RM77.39 Million |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
Malaysia | RM1.49 Billion |
|
Emmbi Industries Limited
NSE:EMMBI
|
India | Rs2.61 Billion |
|
HUTCHMED China Ltd
LSE:HCM
|
UK | GBX501.83 Million |
|
Arvee Laboratories (India) Limited
NSE:ARVEE
|
India | Rs91.40 Million |
|
CHARBONE HYDROGEN CORP.
F:K47
|
Germany | €10.91 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Bcal Diagnostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bcal Diagnostics Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bcal Diagnostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bcal Diagnostics Ltd (2017–2024)
The table below shows the annual total liabilities of Bcal Diagnostics Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$3.69 Million ≈ $2.61 Million |
+0.29% |
| 2023-12-31 | AU$3.68 Million ≈ $2.60 Million |
+16.46% |
| 2022-12-31 | AU$3.16 Million ≈ $2.23 Million |
+232.21% |
| 2021-12-31 | AU$950.42K ≈ $672.48K |
+80.82% |
| 2020-12-31 | AU$525.60K ≈ $371.90K |
+38.09% |
| 2019-12-31 | AU$380.64K ≈ $269.33K |
+629.99% |
| 2018-12-31 | AU$52.14K ≈ $36.89K |
-91.88% |
| 2017-12-31 | AU$641.86K ≈ $454.16K |
-- |
About Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated… Read more